Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-11
2005-10-11
Zucker, Paul A. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S456000, C514S562000, C514S563000
Reexamination Certificate
active
06953812
ABSTRACT:
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
REFERENCES:
patent: 4359474 (1982-11-01), Anderson et al.
patent: 4374130 (1983-02-01), Barcza
patent: 5776954 (1998-07-01), De Laszlo et al.
patent: 5837719 (1998-11-01), De Laszlo et al.
patent: 5880139 (1999-03-01), Chang
patent: 6297269 (2001-10-01), Hulin et al.
patent: 847992 (1998-06-01), None
patent: WO 94/14426 (1994-07-01), None
patent: WO 97/16442 (1997-05-01), None
patent: WO 98/04528 (1998-02-01), None
patent: WO 98/21957 (1998-05-01), None
patent: WO 98/22108 (1998-05-01), None
patent: WO 98/22109 (1998-05-01), None
patent: WO 98/24782 (1998-06-01), None
patent: WO 99/01423 (1999-01-01), None
patent: WO/99/24404 (1999-05-01), None
patent: WO 99/32448 (1999-07-01), None
patent: WO 00/32578 (2000-06-01), None
patent: WO 00/39088 (2000-07-01), None
patent: WO 00/69810 (2000-11-01), None
Holst, J.J., et al., “Immunoneutralization of endogenous Glucagon with monoclonal glucagons antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats” Diabetogogia vol. 37., pp. 985-993 (1994).
C.L. Brand et al., “Role of glucagon in maintenance of euglycemia in Fed and fasted rats”., The American Physiological Society vol. 269., pp. E469-477 (1995).
C.L. Brand et al., Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits. Diabetes., vol. 45., pp. 1076-1083 (1996).
L.J. Jelinek et al., “Expression Cloning and Signaling Properties of The Rat Glucagon Receptor”., Science., vol. 259.,pp. 1614-1616 (1993).
C.G. Unson et al., “Biological Activities of des-His1[Glu9]Glucagon Amide, a Glucagon Antagonist1”., Peptides., vol. 10., Part 6, pp. 1171-1177 (1989).
S. R. Post et al., “Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagons receptor system”., Proc. Natl. Acad. Sci. vol. 90., pp. 1662-1666 (1993).
B.Y. Azizeh et al., “[des His1, des Phe6, Glu9] Glucagon Amide: A Newly Designed “Pure” Glucagon Antagonist” Bioorg Med Chem Lett., vol. 5, Part 16, pp. 1849-1852 (1995).
C.G. Unson et al., “Multiple-site Replacement Analogs of Glucagon”., The Journal of Biological Chemistry., vol. 269., No. 17, pp. 12548-12551 (1994).
Brand et al., “Evidence for a Major Rle of Glucagon in the Hyper-glycemia of Experimental Diabetes” Diabetes., vol. 43., Part. 1, p. 172A (1994).
Brand et al., “Regulation of Insulin and Glucagon Secretion by Glucagon in Vivo”, Diabetes, vol. 44, Part 1, p. 134A (1995).
J.L. Collins et al., “A Non-Peptide Glucagon Receptor Anatagoist”., Jour Med. Chem., vol. 2, Part 9., pp. 915-918 (1992).
P. Madsen et al., Discovery and Structure-Activity Relationship of the First Non-peptide Competitive Human Glucagon Receptor Antagonists. J. Med. Chem. vol. 41., pp. 5150-5157 (1998).
Behrens Carsten
Christensen Inge Thoger
Jorgensen Anker Steen
Kodra Janos Tibor
Lau Jesper
Began, Esq. Marc A.
Bork, Esq. Richard W.
Green, Esq. Reza
Novo Nordisk Inc.
Zucker Paul A.
LandOfFree
Glucagon antagonists/inverse agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon antagonists/inverse agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon antagonists/inverse agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3440370